Abstract A027: Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Introduction Early-onset colorectal cancer (EOCRC) is a distinct clinical entity and a rising global challenge. As presentation and symptom patterns at diagnosis have implications for early detection and prognosis, we aimed to characterize differences between EOCRC and late-onset colorectal cancer (LOCRC) at scale. Methods A retrospective cohort of colorectal cancer (CRC) cases diagnosed 1990-2025 was collected. EOCRC and LOCRC were defined as age <50 and ≥50 years at diagnosis. Presentation mode (symptomatic, emergency, screening, incidental, or unclear) and symptoms at diagnosis were classified using the GPT-4o large language model (LLM) through prompt engineering based on manually curated clinical notes relevant to diagnosis and validated on 500 random samples. Patient-level clinical and demographic data were obtained from institutional datasets. Chi-square and odds ratios were used for comparisons. Results LLM-based classification showed strong agreement with manual review (Cohen’s κ=0.90). Of 41,152 CRC cases, 29% were EOCRC and 71% LOCRC. Stage IV at diagnosis (38% vs 31%, p<0.001) and left-sided primaries (76% vs 66%, p<0.001) were more prevalent in EOCRC compared with LOCRC. EOCRC patients more often presented as symptomatic (72% vs 65%, OR 1.36, 95% CI 1.29-1.44, p<0.001) or emergent (23% vs 20%, OR 1.22, 95% CI 1.15-1.29, p<0.001) and were less often detected by screening (3% vs 12%, OR 0.24, 95% CI 0.21-0.27, p<0.001), whereas no meaningful difference was observed for incidental cases. The symptomatic or emergent presentation of EOCRC was more frequently characterized by abdominal/rectal pain (45% vs 35%, OR 1.49, 95% CI 1.41-1.57), bleeding-related symptoms (49% vs 44%, OR 1.25, 95% CI 1.19-1.32), and changes in bowel habits (30% vs 27%, OR 1.16, 95% CI 1.09-1.23), and less often by anemia (11% vs 16%, OR 0.63, 95% CI 0.58-0.68) or constitutional symptoms (13% vs 16%, OR 0.79, 95% CI 0.73-0.85, p<0.001 for all) compared with LOCRC. The proportion of screening-detected cases rose from 3% to 4% in EOCRC (p=0.007) and 9% to 15% in LOCRC (p<0.001) between 1990-2009 and 2010-2025. After the 2021 national screening guideline update, lowering the starting age from 50 to 45 years, screening-detected cases among 45–49-year-old patients increased from 4% to 13% (p<0.001). Conclusions EOCRC predominantly presents as symptomatic or emergent and at a more advanced stage, underscoring the need for enhanced screening strategies and increased public awareness. Citation Format: Emerik Osterlund, Berta Martin-Cullell, Sebastian Correa Cautino, Mahmoud M. G. Yousef, Songwit Payapwattanawong, Neha Y. Agrawal, Paul M. Roy, Kaysia Ludford, John Paul Y. C. Shen, Xiling Shen, Michael J. Overman, Kanwal P. S. Raghav, Arvind Dasari, Van K. Morris, Christine M. Parseghian, Luisa M. Solis Soto, Michael G. White, Yi-Qian Nancy. You, Victoria Serpas Higbie, Scott Kopetz, Guglielmo Vetere. Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr A027.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract A027: Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis
- Date Crossref
- 10/12/2025
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Texas MD Anderson Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Houston pays non établi dans la noticeInstitution
The University of Texas MD Anderson Cancer Center et Houston.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.